Loading…

Artivion, Inc.AORTCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of medical devices and tissue products for cardiac and vascular surgery, including heart valves, stent grafts and preserved tissue.

Momentum laggard 19
Mkt cap
$905M
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$17.9M
20-day average traded
Fwd P/E
383.6×
forward earnings
ROIC−WACC
-7.4 pp
WACC 9.7%
Hurdle
n/a
no reverse DCF
Next earnings
92 days
18 Feb 2027
Close · USD$18.54
1D+1.5%
1W-7.8%
1M-19.7%
3M-33.7%
6M-18.2%
YTD-59.4%
1Y-58.9%
ATR %7.2%
Beta0.42
52w lowhigh61.6% off high

What Artivion does

Maker of medical devices and tissue products for cardiac and vascular surgery, including heart valves, stent grafts and preserved tissue.

Formerly CryoLife, it was renamed Artivion in 2022 after building out aortic products, notably the JOTEC stent grafts bought in 2017. Sales go to hospitals through direct sales and distributors, while preserved human tissue is processed from donated tissue and shipped to surgeons.

Products and services

  • Mechanical/tissue heart valves
  • Aortic stent grafts
  • Cryopreserved human tissue processing
  • BioGlue surgical sealant

Customers

  • Cardiac & vascular surgeons
  • Hospitals

Where it sits in the supply chain

  • Medical devices
  • Cardiac & vascular surgery devices
  • Heart valves, stent grafts, and…

What could go right

  • Aortic disease treatment procedure growth
  • International market expansion

What could go wrong

  • Niche market with larger, better-funded competitors
  • Product liability/regulatory risk

Moat: narrow (regulatory licence, brand, installed base). Niche cardiac/vascular device and tissue-processing brands built over decades, though smaller-scale than majors.

Headquarters: Atlanta, Georgia · Founded: 1997 · Employees: 1,800

Named competitors

Artivion at a glance

Size Artivion (AORT) is a United States Health Care company (Medical Specialties) with a market value of $905M, the 2294th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.54 on 18 Nov 2026.

Performance Over six months the shares fell 18.2%, against -12.1% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 14.0% over the last twelve months (peer median +6.0%); the operating margin is 4.9% (peer median 9.6%).

Valuation It trades at 383.6× forward earnings against a peer median of 21.7× (most expensive of 17).

Capital Return on invested capital runs 7.4 points below its cost of capital (9.7% WACC).

Short interest Short interest is 7.0% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 88AORT 81
Six months, rebased to 100: Artivion against the median of its 20 peers (local-currency closes).

Artivion financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$482M$441M$389M$354M$314M
Revenue growth—+14%+10%+13%—
Gross profit$289M$270M$233M$214M$187M
EBITDA$49.8M$56.6M$51.7M$37.9M$37.4M
Net income-$17.6M$9.76M-$13.3M-$30.6M-$19.1M
Free cash flow-$42.6M$839,000$11.0M$11.1M-$14.2M
Capital expenditure$59.3M$39.0M$11.2M$7.43M$10.7M
Total debt$407M$259M$362M$359M$357M

Quarterly statements and history in the cockpit →

Artivion competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%KURNBVS3015806885756887676886266882772906507780002658688656SFL301602304677303600300143KIDSAORT6-month return →1-month return →
Up and to the right = strong over both horizons. Artivion is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×KURNBVS3015806885756887676886267780002658688656SFL304677306033671187300143AORTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Artivion is the large dot.

Artivion competitors and peer comparison

Head to head with its named competitors (AORT vs MDT vs EW vs ABT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Artivion AORT$905M-18%+14%5%383.6×n/a
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Edwards Lifesciences EW$60.5B+27%+13%29%32.3×17.1%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
LeMaitre Vascular LMAT$1.73B-25%+12%28%24.5×2.9%

How Artivion compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Artivion against its 20 peers (data as of 18 Nov 2026)
MeasureAORTPeer medianRank in peer set
1-month return-19.7%-6.3%3rd lowest of 21
6-month return-18.2%-12.1%8th lowest of 21
Distance from 52-week high-61.6%-38.6%2nd lowest of 21
Revenue growth (TTM)+14.0%+6.0%8th highest of 21
Operating margin4.9%9.6%5th lowest of 21
Forward P/E383.6×21.7×most expensive of 17
ROIC minus cost of capital-7.4 pp+2.9 pp3rd lowest of 21
EV / EBITDA25.3×9.9×3rd most expensive of 9
Net debt / EBITDA7.2×0.3×2nd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a

Questions

Who are Artivion's main competitors?
Named competitors: Medtronic (MDT), Edwards Lifesciences (EW), Abbott Laboratories (ABT), LeMaitre Vascular (LMAT). The cockpit's measured peer set (industry) also includes Kuros Biosciences (KURN.SW), Bioventus (BVS), Aidite (Qinhuangdao) Technology (301580.SZ), Shenzhen YHLO Biotech (688575.SS), Hangzhou Biotest Biotech (688767.SS), Xiangyu Medical (688626.SS).
Is Artivion expensive compared with its peers?
On forward p/e it trades at 383.6× against a peer median of 21.7×, most expensive of 17 in its peer set.
How has Artivion stock performed?
Over six months to 18 Nov 2026 the shares returned -18.2% against -12.1% for the median peer; over one year -58.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.